Moral & Partners has advised Turkish private equity fund Taxim Capital on its investment in Moltek A.S. through Luxembourg subsidiary LuxTheranostics. Acar & Ergonen advised Moltek’s shareholders.
Financial details were not disclosed.
Moltek is a Turkish radiopharmaceuticals producer established in 2007. It specializes in nuclear medicine and its products are used in oncology, neurology, and cardiology.
The Moral & Partners team was led by Partners Resat Moral and Serkan Pamukkale and included Senior Associates Karaca Kacar, Serra Haviyo, and Duygu Bozkurt and Associate Dilara Kaymaz.
The Acar & Ergonen team included Partners Duygu Acar Yucesoy and Asli Tezcan and Associates Beyza Akinci and Pinar Akkaya.
